<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the treatment of myelodysplastic syndromes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the treatment of myelodysplastic syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the treatment of myelodysplastic syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mikkael A Sekeres, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Uwe Platzbecker, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H515103"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myelodysplastic syndromes (MDS) comprise a group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia), and abnormal cellular maturation. Patients are at risk for symptoms related to anemia, infection, and bleeding, and they have variable rates of transformation to acute myeloid leukemia (AML). (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p>This topic will provide an overview of the treatment of MDS. </p><p>Detailed discussions of the following issues are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes", section on 'Allogeneic HCT'</a>.)</p><p></p><p class="headingAnchor" id="H2688483988"><span class="h1">MDS CATEGORY</span><span class="headingEndMark"> — </span>Prior to choosing a course of treatment, the diagnosis of MDS must be verified, other conditions in the differential diagnosis should be excluded, the World Health Organization (WHO) category should be determined, and a prognostic risk category assigned.</p><p class="headingAnchor" id="H3789992272"><span class="h2">Verify the diagnosis</span><span class="headingEndMark"> — </span>Prior to choosing a course for management, the diagnosis of MDS must be verified and other disorders in the differential diagnosis excluded.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow evaluation</strong> – A bone marrow specimen is required for the diagnosis of MDS. The specimen should be analyzed for morphology, immunophenotype, cytogenetics, and molecular findings, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Bone marrow examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of MDS requires: cytopenia in at least one blood lineage, morphologic dysplasia in ≥10 percent of nucleated cells in at least one lineage, &lt;20 percent blasts in blood and bone marrow, and/or characteristic cytogenetic or molecular findings, without evidence of an alternate cause of these findings. Further details of the diagnosis of MDS are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exclude other conditions</strong> – Other conditions in the differential diagnosis can be excluded by evaluation of the bone marrow specimen, including histology and selected laboratory studies. Other conditions that may resemble MDS include (see  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Differential diagnosis'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytopenias and/or dysplasia</strong> – Nutritional deficiencies (eg, folate, <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>, copper deficiency), medications, toxic exposures (eg, alcohol, heavy metals), infections (eg, HIV, parvovirus B19), autoimmune conditions (eg, systemic lupus erythematosus), or heritable or acquired causes of dysplasia. (See  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia"</a> and  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clonal hematopoiesis</strong> – Clonal hematopoiesis of indeterminate potential (CHIP), idiopathic cytopenia of undetermined significance (ICUS), clonal cytopenia of undetermined significance (CCUS), aplastic anemia (AA)/paroxysmal nocturnal hemoglobinuria (PNH). (See  <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">"Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis"</a> and  <a class="medical medical_review" href="/z/d/html/121985.html" rel="external">"Idiopathic and clonal cytopenias of uncertain significance (ICUS and CCUS)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other myeloid neoplasms</strong> – Acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), MDS/MPN syndromes (eg, chronic myelomonocytic leukemia), myelofibrosis. (See  <a class="medical medical_review" href="/z/d/html/94786.html" rel="external">"Acute myeloid leukemia in adults: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">"Clinical manifestations and diagnosis of chronic myeloid leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p></p><p class="headingAnchor" id="H1445739657"><span class="h2">MDS classification</span><span class="headingEndMark"> — </span>MDS should be categorized according to the WHO classification [<a href="#rid1">1,2</a>]. The WHO classification system has replaced the outdated French-American-British (FAB) system. (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p>The WHO classification of MDS is based on the number of cytopenic and dysplastic lineages, percentage of blasts and ring sideroblasts, and cytogenetic findings, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>MDS with single lineage dysplasia</p><p class="bulletIndent1"><span class="glyph">●</span>MDS with multilineage dysplasia</p><p class="bulletIndent1"><span class="glyph">●</span>MDS with ring sideroblasts</p><p class="bulletIndent1"><span class="glyph">●</span>MDS with isolated del(5q)</p><p class="bulletIndent1"><span class="glyph">●</span>MDS with excess blasts</p><p class="bulletIndent1"><span class="glyph">●</span>MDS, unclassifiable</p><p></p><p class="headingAnchor" id="H2399386211"><span class="h1">PROGNOSTIC CATEGORY</span><span class="headingEndMark"> — </span>Assignment of a risk category is important for sharing prognostic information with the patient and for selecting treatment. We suggest using the revised international prognostic scoring system (IPSS-R)  (<a class="graphic graphic_table graphicRef85832" href="/z/d/graphic/85832.html" rel="external">table 1</a>) (<a class="calc calc_professional" href="/z/d/html/85970.html" rel="external">calculator 1</a>) or the original IPSS  (<a class="graphic graphic_table graphicRef50634" href="/z/d/graphic/50634.html" rel="external">table 2</a>) (<a class="calc calc_professional" href="/z/d/html/13485.html" rel="external">calculator 2</a>), which are based on the percentage of bone marrow blasts, number and severity of cytopenias, and cytogenetic findings. We categorize patients as follows [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-risk MDS</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IPSS-R: ≤3.5 points</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IPSS: ≤1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk MDS</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IPSS-R: ≥4.0 points</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IPSS: ≥1.5 points</p><p></p><p>Further details of these and other prognostic models are presented separately. (See  <a class="medical medical_review" href="/z/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults", section on 'IPSS (Original IPSS)'</a>.)</p><p class="headingAnchor" id="H774138602"><span class="h1">MEDICAL FITNESS</span><span class="headingEndMark"> — </span>Medical fitness is determined by clinical and laboratory evaluation, performance status, and severity of comorbid conditions. Classification of medical fitness is important for choosing treatment of MDS. In judging medical fitness, it is important to recognize that age, per se, does not determine medical fitness. Additional information for judging medical fitness, especially in older patients, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86177.html" rel="external">"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults"</a>.)</p><p class="headingAnchor" id="H1223255779"><span class="h2">Clinical and laboratory evaluation</span><span class="headingEndMark"> — </span>Pretreatment clinical evaluation and laboratory studies should assess the nature and severity of symptoms, degree and complications of cytopenias, and comorbid conditions that may affect treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical </strong>–<strong> </strong>The clinical evaluation should assess findings related to cytopenias and seek to identify factors that may exacerbate these conditions. This should include assessment of clinical consequences of anemia (eg, dyspnea, weakness, history of transfusions), thrombocytopenia (eg, bleeding, bruising), and neutropenia (eg, recurrent or severe infections). Clinical manifestations of comorbid illnesses, including heart disease, pulmonary processes, and renal impairment should be documented.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count, differential count, reticulocyte count, prothrombin time (PT), partial thromboplastin time (PTT)</p><p class="bulletIndent2"><span class="glyph">•</span>Electrolytes, renal and liver function tests (including lactate dehydrogenase [LDH])</p><p class="bulletIndent2"><span class="glyph">•</span>Serum iron, total iron-binding capacity, ferritin, <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>, folate</p><p class="bulletIndent2"><span class="glyph">•</span>Serum erythropoietin (EPO)</p><p class="bulletIndent2"><span class="glyph">•</span>Serology for HIV and hepatitis B and C</p><p></p><p class="headingAnchor" id="H1410499536"><span class="h2">Fitness assessment instruments</span><span class="headingEndMark"> — </span>Assessment of medical fitness can be judged by the following instruments:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – Eastern Cooperative Oncology Group (ECOG) performance status (PS) scale  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>) is useful for assessing activities of daily living (ADL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiologic fitness</strong> – We use the Charlson comorbidity index (CCI)  (<a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">table 4</a>) to assess the severity of comorbid conditions, ADL, physical performance tests, and cognition. Other instruments such as the short physical performance battery (SPPB) are also acceptable.</p><p></p><p class="bulletIndent1">For some older patients, a comprehensive geriatric assessment and geriatric consultation may aid assessment of the medical fitness, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86177.html" rel="external">"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults", section on 'Pretreatment evaluation'</a>.) </p><p></p><p class="headingAnchor" id="H75628451"><span class="h2">Fitness categories</span><span class="headingEndMark"> — </span>We classify patients according to their medical fitness for treatment, based on PS and physiologic fitness, as described above.</p><p>There are no clear distinctions between fitness categories, and some measures of PS or physiologic fitness can apply to different categories of fitness. Chronic comorbid conditions should be weighed more heavily than transient medical complications of the leukemia itself (eg, infection due to neutropenia, heart failure exacerbated by anemia).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medically-fit</strong> – Medically-fit patients are those who are considered able to tolerate intensive treatment for acute myeloid leukemia (AML), based on <strong>both</strong> of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ECOG PS  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>): 0 to 2</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CCI  (<a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">table 4</a>): 0 to 2</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medically-unfit, but not frail</strong> – Patients who are medically-unfit but not frail are unlikely to tolerate intensive treatments because of impaired PS or comorbid conditions. This category includes a broad range of physical function; some have only modest, recent, or transient impairment of functional status, while others have substantial comorbid illnesses, cognitive impairment, or other conditions that may affect their ability to tolerate treatment.</p><p></p><p class="bulletIndent1">We judge patients to be medically-unfit but not frail if <strong>either</strong> of the following applies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ECOG PS  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>): 3</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CCI  (<a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">table 4</a>): 3</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frail</strong> – Frail patients are those whose debility or comorbid conditions would not permit treatment aimed at modifying the disease course, as reflected by <strong>both</strong> the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ECOG PS  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>): &gt;3</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CCI  (<a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">table 4</a>): &gt;3</p><p></p><p class="headingAnchor" id="H109646236"><span class="h1">GOALS OF CARE</span><span class="headingEndMark"> — </span>Goals of care should be established in discussions between the patient and clinicians at the time of diagnosis and periodically through the course of the disease.</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with MDS, the goals of care are to lessen symptoms, improve the quality of life, and prolong survival, while minimizing treatment-related toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allogeneic hematopoietic cell transplantation (HCT) is the treatment with the highest potential to cure MDS. However, because of advanced age, comorbid conditions, lack of adequately matched donors, and/or patient preferences, only a small subset of patients with MDS are candidates for allogeneic HCT.</p><p></p><p class="headingAnchor" id="H277610262"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>MDS is a heterogeneous disease and treatment should be individualized. We encourage participation in a clinical trial, when possible.</p><p>Selection of treatment is influenced by the severity of symptoms and cytopenias, MDS classification, prognostic category, medical fitness, and patient preferences. (See <a class="local">'Medical fitness'</a> above and <a class="local">'Prognostic category'</a> above.)</p><p>Our approach is similar to that proposed by the MDS Panel for Practice Guidelines of the National Comprehensive Cancer Network (NCCN), British Committee for Standards in Haematology, European Society of Medical Oncology, and the European LeukemiaNet [<a href="#rid4">4-8</a>].</p><p class="headingAnchor" id="H3354055491"><span class="h2">Lower-risk MDS</span><span class="headingEndMark"> — </span>For patients with lower-risk MDS, we offer treatment based on the severity of cytopenias and symptoms  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>). </p><p>We consider symptomatic patients to manifest any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – Symptoms related to anemia (eg, dyspnea, fatigue, weakness) and hemoglobin (Hb) &lt;10 g/dL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia – Platelets &lt;20,000/microL or excessive bleeding or bruising with platelets &lt;50,000/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia – Recurrent and/or severe infections in the setting of persistent absolute neutrophil count (ANC) &lt;500 neutrophils/microL or ANC &lt;1000 neutrophils/microL with recurrent or infections</p><p></p><p class="headingAnchor" id="H3507995222"><span class="h3">Asymptomatic</span><span class="headingEndMark"> — </span>For asymptomatic patients, we generally offer monitoring rather than immediate treatment  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>), because there is no evidence that early treatment of asymptomatic lower-risk MDS improves long-term survival and deferral of treatment precludes potential treatment-related adverse events. </p><p>Asymptomatic patients should be followed expectantly to evaluate the tempo of disease; receive supportive care, if needed (eg, antibiotics for bacterial infections, transfusions for critical cytopenias prior to surgery); and have age-appropriate health maintenance (eg, vaccinations, counseling for smoking cessation, healthy diet, weight control, screening for other cancers). (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Asymptomatic patients'</a>.)</p><p class="headingAnchor" id="H1035773577"><span class="h3">Symptomatic</span><span class="headingEndMark"> — </span>Symptomatic patients with lower-risk MDS are treated according to the severity of cytopenias and symptoms, such as ongoing transfusion requirements, progressive cytopenias, or a declining quality of life.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-intensity therapies</strong> – For most symptomatic patients with lower-risk MDS, we treat with a lower-intensity therapy, supplemented by supportive care as needed. Lower-intensity treatments can lessen symptoms, improve the quality of life, and may lengthen survival, but they are not curative.</p><p></p><p class="bulletIndent1">The choice of a lower-intensity treatment is guided by which cell lineages are affected, laboratory findings (eg, serum erythropoietin [EPO]), MDS classification (eg, cytogenetic and molecular findings), drug availability, and patient preferences  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Symptomatic MDS'</a>.)</p><p></p><p class="bulletIndent1">Examples of lower-intensity treatments include growth factors (eg, <a class="drug drug_general" data-topicid="9410" href="/z/d/drug information/9410.html" rel="external">epoetin alfa</a>, thrombopoietin receptor agonists), <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a>, hypomethylating agents (HMA; eg, <a class="drug drug_general" data-topicid="8797" href="/z/d/drug information/8797.html" rel="external">azacitidine</a>, <a class="drug drug_general" data-topicid="8855" href="/z/d/drug information/8855.html" rel="external">decitabine</a>), immunosuppressive therapy, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and targeted agents (eg, IDH inhibitors). These treatments are generally administered in the outpatient setting and they have a low risk of treatment-related morbidity and mortality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intensive treatments</strong> – Some patients (typically younger, medically-fit individuals) with more advanced lower-risk MDS or adverse features that are not represented with current scoring systems may choose intensive approaches that can alter the natural history of MDS but are associated with substantial morbidity and mortality. Intensive approaches (eg, intensive remission induction chemotherapy, allogeneic hematopoietic cell transplantation [HCT]) may be selected because the patient places greater value on long-term disease control and the potential for a prompt response than on the treatment-related toxicity and/or mortality. (See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes", section on 'Intensive chemotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care alone</strong> – Some patients may decline specific treatment for MDS and opt for supportive care alone, based on frailty or personal values and preferences. (See  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS"</a>.)</p><p></p><p class="headingAnchor" id="H1137771185"><span class="h2">Higher-risk MDS</span><span class="headingEndMark"> — </span>Treatment choices for patients with higher-risk MDS are informed by medical fitness, pathologic features, and personal values. Assessment of medical fitness is discussed above. (See <a class="local">'Medical fitness'</a> above.)</p><p class="headingAnchor" id="H1333032663"><span class="h3">Medically-fit</span><span class="headingEndMark"> — </span>A wide range of treatment options is available to the medically-fit patient with higher-risk MDS. Age, per se, does not govern the choice of treatment, but caution is appropriate when considering intensive approaches for patients ≥75 years, because their benefits and toxicities have been defined primarily in younger patients. We encourage early evaluation by transplant specialists to determine eligibility for allogeneic HCT. (See  <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p>There is no optimal treatment for all medically-fit patients, and the approach varies by institution. The choice of therapy is influenced by adverse pathologic features (eg, <em>TP53</em> mutation, adverse cytogenetic abnormalities), presence of mutations that are amenable to a targeted agent (eg, IDH inhibitors)  (<a class="graphic graphic_algorithm graphicRef119697" href="/z/d/graphic/119697.html" rel="external">algorithm 2</a>), availability of a stem cell donor and caregiver, and individual values and preferences.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intensive treatments</strong> – Medically-fit patients may be candidates for intensive remission induction chemotherapy, with or without allogeneic HCT. Intensive treatments that include allogeneic transplantation have the potential to achieve long-term disease-free survival, but they are associated with considerable short-term and long-term toxicity. Discussion of intensive therapies, outcomes, and adverse effects is presented separately. (See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes", section on 'Patients suitable for intensive treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-intensity therapies</strong> – Some patients may instead choose lower-intensity therapy (eg, HMA alone or with other agents, targeted agents)  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>). This approach is associated with more modest toxicity (eg, neutropenic infections) and can provide relief of symptoms, improve the quality of life, and extend survival, but is not curative and does not preclude later use of more intensive approaches. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Symptomatic MDS'</a>.)</p><p></p><p class="headingAnchor" id="H403728381"><span class="h3">Medically-unfit, but not frail</span><span class="headingEndMark"> — </span>There is no optimal treatment for patients who are medically-unfit, but not frail; this fitness category includes a wide spectrum of patients. Most are treated with lower-intensity therapies, while others may choose supportive care alone. If reduced fitness is disease-related, it may improve with treatment.</p><p>Selection of treatment is informed by the patient's goals of care and personal preferences, institutional approach, and genetic features of the MDS cells:</p><p class="bulletIndent1"><span class="glyph">●</span>Management of the patient who is eligible for intensive treatment (eg, intensive remission induction chemotherapy, allogeneic HCT) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes", section on 'Patients suitable for intensive treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are not candidates or who decline intensive treatments, we favor lower-intensity therapy, with the choice of therapy based on pathologic features, drug availability, and patient preference  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Lower intensity agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients may choose to receive supportive care alone, as described for frail patients.</p><p></p><p class="headingAnchor" id="H1442181816"><span class="h3">Frail</span><span class="headingEndMark"> — </span>Frail patients are unlikely to tolerate treatment other than supportive care. (See  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS"</a>.)</p><p class="headingAnchor" id="H3117624598"><span class="h1">RESPONSE ASSESSMENT AND MONITORING</span><span class="headingEndMark"> — </span>Patients should be evaluated to determine the response to therapy, monitor for disease progression, and assess possible treatment- or disease-related complications. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Monitoring'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – Response to therapy is primarily assessed by alleviation of symptoms, improved blood and/or blast counts, reduced transfusion needs, and improved quality of life. Particularly for patients with higher-risk disease, some clinicians favor assessing response with a bone marrow examination after two to four cycles of therapy, but for patients with lower-risk disease, we generally reserve bone marrow examinations for evaluation of possible disease progression based on an unanticipated deterioration of blood counts or other worrisome clinical findings.</p><p></p><p class="bulletIndent1">It should be recognized that most patients respond slowly to lower-intensity agents; a meaningful improvement may require three or more months of treatment. Patients should remain on therapy for as long as they are deriving benefit and not experiencing significant adverse effects. For patients who experience significant adverse effects, we judiciously reduce the drug dose or offer brief treatment delays rather than abandoning the treatment, especially if there is evidence of a response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – The schedule and protocol for follow-up should be individualized according to the severity of symptoms and cytopenias and concerns on the part of the patient and clinician.</p><p></p><p class="bulletIndent1">We perform a focused history and physical examination, complete blood count with differential, and other laboratory studies, as clinically indicated. Patients should be educated regarding potential complications of MDS and asked to call the office promptly if they develop a fever or bleeding.</p><p></p><p class="headingAnchor" id="H515614"><span class="h1">TREATMENT OF RECURRENT OR REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>For patients who do not respond adequately to initial therapy or have worsening symptoms or disease progression after an earlier response, we select subsequent management based on prior therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>Disease re-evaluation – The extent of re-evaluation for a patient who relapses after an initial response to therapy should be guided by the clinical presentation. For patients who develop sudden/dramatic changes in blood counts or increasing blasts on the peripheral smear, we perform a bone marrow examination to assess disease progression. For modest changes in blood counts or symptoms, repeating a bone marrow examination is generally not necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment – Patients should be encouraged to participate in clinical trials, when available. Treatment options for patients with refractory or recurrent disease are influenced by prior therapy, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Second-line and later treatment'</a>.)</p><p></p><p class="headingAnchor" id="H515621"><span class="h1">CLINICAL TRIALS</span><span class="headingEndMark"> — </span>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=16122" target="_blank">www.clinicaltrials.gov</a>). For interested patients, relatives, and physicians, the Aplastic Anemia and MDS International Foundation maintains a website (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aamds.org%2F&amp;token=IQxLzDq4doJGUgaZgeIY07FrtZDjBJHdGUtMGtxT3kA%3D&amp;TOPIC_ID=16122" target="_blank">www.aamds.org</a>), which contains additional information as well as a listing of clinical trials in this disorder [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3853433523"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116777.html" rel="external">"Society guideline links: Myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H515628"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16328.html" rel="external">"Patient education: Myelodysplastic syndromes (MDS) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15854.html" rel="external">"Patient education: Autologous bone marrow transplant (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/692.html" rel="external">"Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H516101"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Myelodysplastic syndromes (MDS) are hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia), abnormal cellular maturation, and predisposition to progress to acute myeloid leukemia (AML).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and classification</strong> – Diagnosis and classification is based on World Health Organization (WHO) classification. (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic category</strong> – The revised international prognostic scoring system (IPSS-R)  (<a class="graphic graphic_table graphicRef85832" href="/z/d/graphic/85832.html" rel="external">table 1</a>) (<a class="calc calc_professional" href="/z/d/html/85970.html" rel="external">calculator 1</a>) or the original IPSS  (<a class="graphic graphic_table graphicRef50634" href="/z/d/graphic/50634.html" rel="external">table 2</a>) (<a class="calc calc_professional" href="/z/d/html/13485.html" rel="external">calculator 2</a>) use bone marrow blast percentage, cytopenias, and cytogenetic findings to classify prognosis (see  <a class="medical medical_review" href="/z/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults", section on 'IPSS (Original IPSS)'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower-risk MDS</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IPSS-R: ≤3 points</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IPSS: ≤1 point</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher-risk MDS</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IPSS-R: ≥3.5 points</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IPSS: ≥1.5 points</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical fitness</strong> – Medical fitness is determined by clinical and laboratory evaluation, performance status (PS)  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>), and comorbid conditions  (<a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">table 4</a>) as (see <a class="local">'Fitness categories'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medically-fit</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medically-unfit, but not frail</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frail</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of care</strong> – Goals of care are to lessen symptoms, improve quality of life, and prolong survival, while minimizing treatment-related toxicity. Some patients are candidates for intensive, potentially curative therapies. (See <a class="local">'Goals of care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-risk MDS</strong> <strong>management</strong> – Management is guided by symptoms and cytopenias  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>) (see <a class="local">'Lower-risk MDS'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic</strong> – We offer monitoring rather than immediate treatment, to avoid treatment-related adverse events (AEs) and because early treatment does not improve long-term survival. (See <a class="local">'Asymptomatic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic</strong> – Treatment is guided by severity of cytopenias and symptoms (eg, transfusion requirements, progressive cytopenias, a declining quality of life). Lower-intensity therapies (eg, <a class="drug drug_general" data-topicid="9410" href="/z/d/drug information/9410.html" rel="external">epoetin alfa</a>, growth factors, iron chelation, <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a>, hypomethylating agents, immunosuppressive therapy, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, or a targeted agent (eg, IDH inhibitor) have modest AEs, but are not curative. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Symptomatic MDS'</a>.)</p><p></p><p class="bulletIndent2">Occasional patients with lower-risk MDS may choose intensive approaches that can alter the natural history, but they are associated with substantial morbidity and mortality. (See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes", section on 'Intensive chemotherapy'</a>.)</p><p></p><p class="bulletIndent2">Some patients opt for supportive care alone, based on frailty or personal values. (See  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk MDS management</strong> – Treatment is informed by medical fitness, pathologic features, and personal values. (See <a class="local">'Higher-risk MDS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medically-fit</strong> – Treatment may include intensive or lower-intensity therapies, as guided by pathologic features (eg, <em>TP53</em> mutation, adverse cytogenetics), targetable mutations  (<a class="graphic graphic_algorithm graphicRef119697" href="/z/d/graphic/119697.html" rel="external">algorithm 2</a>), suitability for transplantation, and personal preferences. (See  <a class="medical medical_review" href="/z/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes", section on 'Intensive chemotherapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medically-unfit, but not frail</strong> – We favor lower-intensity therapy, based on pathologic features, drug availability, and patient preference  (<a class="graphic graphic_algorithm graphicRef127072" href="/z/d/graphic/127072.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Lower intensity agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frail</strong> – Supportive care alone. (See  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent or refractory disease</strong> – Treatment for relapsed or refractory MDS is based on prior therapy. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Second-line and later treatment'</a>.)</p><p></p><p class="headingAnchor" id="H3210054350"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Elihu H Estey, MD, who contributed as an author for this topic review.</p><p>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as author on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">Pfeilstöcker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood 2016; 128:902.</a></li><li class="breakAll">http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf (Accessed on September 28, 2013).</li><li><a class="nounderline abstract_t">Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122:2943.</a></li><li><a class="nounderline abstract_t">Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol 2014; 164:503.</a></li><li><a class="nounderline abstract_t">Fenaux P, Haase D, Sanz GF, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3:iii57.</a></li><li><a class="nounderline abstract_t">Platzbecker U. Treatment of MDS. Blood 2019; 133:1096.</a></li><li class="breakAll">www.aamds.org/aplastic (Accessed on July 12, 2011).</li></ol></div><div id="topicVersionRevision">Topic 16122 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27335276" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Time-dependent changes in mortality and transformation risk in MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27335276" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Time-dependent changes in mortality and transformation risk in MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980065" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24372298" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Guidelines for the diagnosis and management of adult myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25185242" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30670446" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of MDS.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
